SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/82588"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/82588" > Chemoendocrine comp...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005295naa a2201021 4500
001oai:gup.ub.gu.se/82588
003SwePub
008240410s2008 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/825882 URI
0247 a https://doi.org/10.1200/JCO.2007.10.63932 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Viale, Giuseppe4 aut
2451 0a Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
264 1c 2008
520 a PURPOSE: To centrally assess estrogen receptor (ER) and progesterone receptor (PgR) levels by immunohistochemistry and investigate their predictive value for benefit of chemo-endocrine compared with endocrine adjuvant therapy alone in two randomized clinical trials for node-negative breast cancer. PATIENTS AND METHODS: International Breast Cancer Study Group Trial VIII compared cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for 6 cycles followed by endocrine therapy with goserelin with either modality alone in pre- and perimenopausal patients. Trial IX compared three cycles of CMF followed by tamoxifen for 5 years versus tamoxifen alone in postmenopausal patients. Central Pathology Office reviewed 883 (83%) of 1,063 patients on Trial VIII and 1,365 (82%) of 1,669 on Trial IX and determined ER and PgR by immunohistochemistry. Disease-free survival (DFS) was compared across the spectrum of expression of each receptor using the Subpopulation Treatment Effect Pattern Plot methodology. RESULTS: Both receptors displayed a bimodal distribution, with substantial proportions showing no staining (receptor absent) and most of the remainder showing a high percentage of stained cells. Chemo-endocrine therapy yielded DFS superior to endocrine therapy alone for patients with receptor-absent tumors, and in some cases also for those with low levels of receptor expression. Among patients with ER-expressing tumors, additional prediction of benefit was suggested in absent or low PgR in Trial VIII but not in Trial IX. CONCLUSION: Low levels of ER and PgR are predictive of the benefit of adding chemotherapy to endocrine therapy. Low PgR may add further prediction among pre- and perimenopausal but not postmenopausal patients whose tumors express ER.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Adult
653 a Aged
653 a Antineoplastic Agents
653 a Hormonal
653 a therapeutic use
653 a Antineoplastic Combined Chemotherapy Protocols
653 a administration & dosage
653 a therapeutic use
653 a Breast Neoplasms
653 a chemistry
653 a drug therapy
653 a surgery
653 a Chemotherapy
653 a Adjuvant
653 a Cyclophosphamide
653 a administration & dosage
653 a Disease-Free Survival
653 a Female
653 a Fluorouracil
653 a administration & dosage
653 a Goserelin
653 a administration & dosage
653 a Humans
653 a Immunohistochemistry
653 a Menopause
653 a Methotrexate
653 a administration & dosage
653 a Middle Aged
653 a Neoplasms
653 a Hormone-Dependent
653 a chemistry
653 a drug therapy
653 a Predictive Value of Tests
653 a Receptors
653 a Estrogen
653 a analysis
653 a Receptors
653 a Progesterone
653 a analysis
653 a Tamoxifen
653 a administration & dosage
653 a Treatment Outcome
653 a Tumor Markers
653 a Biological
653 a analysis
7001 a Regan, Meredith M4 aut
7001 a Maiorano, Eugenio4 aut
7001 a Mastropasqua, Mauro G4 aut
7001 a Golouh, Rastko4 aut
7001 a Perin, Tiziana4 aut
7001 a Brown, Robert W4 aut
7001 a Kovács, Anikó,d 1961u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xkovan
7001 a Pillay, Komala4 aut
7001 a Ohlschlegel, Christian4 aut
7001 a Braye, Stephen4 aut
7001 a Grigolato, Piergiovanni4 aut
7001 a Rusca, Tiziana4 aut
7001 a Gelber, Richard D4 aut
7001 a Castiglione-Gertsch, Monica4 aut
7001 a Price, Karen N4 aut
7001 a Goldhirsch, Aron4 aut
7001 a Gusterson, Barry A4 aut
7001 a Coates, Alan S4 aut
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org
7730 t Journal of clinical oncology : official journal of the American Society of Clinical Oncologyg 26:9, s. 1404-10q 26:9<1404-10x 1527-7755
8564 8u https://gup.ub.gu.se/publication/82588
8564 8u https://doi.org/10.1200/JCO.2007.10.6393

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy